InMed Pharmaceuticals (INM) Capital Expenditures Growth (1y) (2020 - 2023)
InMed Pharmaceuticals (INM) Capital Expenditures Growth (1y) (2020 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.64 Mn | 1.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 43.38% |
| Jun 30, 2023 | 143.37% |
| Sep 30, 2022 | -102.20% |
| Jun 30, 2022 | 646.90% |
| Dec 31, 2021 | -166,353.25% |
| Sep 30, 2021 | 1,684.82% |
| Jun 30, 2021 | -1,247.35% |
| Dec 31, 2020 | -92.91% |
| Sep 30, 2020 | -56.94% |